Compare TPCS & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPCS | CALC |
|---|---|---|
| Founded | 1956 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.1M | 19.1M |
| IPO Year | 2008 | 2020 |
| Metric | TPCS | CALC |
|---|---|---|
| Price | $5.80 | $1.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 59.3K | ★ 286.9K |
| Earning Date | 02-17-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.38 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $31,644,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.88 | $0.44 |
| 52 Week High | $6.31 | $7.20 |
| Indicator | TPCS | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 58.40 | 73.36 |
| Support Level | $4.41 | $0.53 |
| Resistance Level | $6.31 | $2.47 |
| Average True Range (ATR) | 0.20 | 0.11 |
| MACD | -0.03 | 0.15 |
| Stochastic Oscillator | 72.69 | 78.22 |
Techprecision Corp manufactures precision, large-scale fabricated and machined metal structural components and systems. The company provides end-to-end services, transforming raw materials into precision finished products through custom fabrication, precision machining, assembly, integration, inspection, non-destructive evaluation, and testing. It manufactures products in accordance with customers' drawings and specifications while complying with applicable national and international industry codes and standards. Its segments are: Ranor, which generates the majority of revenue, and Stadco, both focused on the manufacture and assembly of components mainly for defense and other precision industrial customers.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.